PRA conducted a survey at the 2018 Alzheimer's Association International Conference in Chicago. Across the board we found that the research community remains optimistic for a cure or disease modifying treatment for Alzheimer’s, with particular faith in the amyloid hypothesis. Industry, advocacy groups, academia, and many other stakeholders in clinical development continue to embrace new technologies and data science with the hope that one day these will contribute toward bringing treatments to the right patients at the right stage of the disease.
PRA Cool Under Deadline Pressure
PRA was selected to perform a Phase II colorectal cancer trial due to our knowledge from previous colorectal studies as well as our evidence-based…
PRA Successfully Delivers A Complex Phase I Psoriasis Study
Exceptional Support and Innovative Strategies Combat Study Challenges.